CD200 and Miyoshi myopathy: Interestingly, the cumulative incidence of MM progression after first-line treatment was not different between genetic groups when considering the whole cohort at 5 years (59.8% for patients with the CD200 rs1131199 GG genotype and 66.3% for patients with CC or CG genotype; p: 0.687) (Figure 3).